NDAQ:SAVA) Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc. (SAVA) of a Class Action Lawsuit and an Upcoming Deadline ...

Cassava Sciences' failed trials, limited cash for strategic pivots, and lack of clear direction create significant downside ...

An Austin biotech company is laying off a third of its staff following news that its primary drug candidate didn't produce ...

Cassava Sciences is laying off 10 employees —a third of its workforce—as the biotech seeks to conserve cash in the wake of ...

NEW YORK, Jan. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment ...

Cassava Sciences Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -76.28%. The profit margin, also known as the revenue ratio or gross profit ratio, ...

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Joe Edelman, a legendary biotech investor, warns that shorting industry stocks isn’t easy. He has become a billionaire, ...

Austin-area robotic architecture firm ICON and pharmaceutical company Cassava Sciences combined to layoff over 120 workers ...